Kalvista Pharmaceuticals Inc expected to post a loss of 86 cents a share - Earnings Preview

Kalvista Pharmaceuticals

04/09/2023 13:34

* Kalvista Pharmaceuticals Inc  KALV.OQ   KALV.O  is
expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Kalvista
Pharmaceuticals
Inc is for a loss of 86 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kalvista
Pharmaceuticals Inc is $20​, above​ its last closing price
of $10.66. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Apr. 30 2023  -0.83       -0.94      -0.77     Beat    17.9
 Jan. 31 2023  -0.92       -0.98      -0.75     Beat    23.9
 Oct. 31 2022  -1.03       -1.06      -0.90     Beat    14.8​
 Jul. 31 2022  -1.03       -1.04      -0.94     Beat    9.6
 ​​Apr.        -1.07       -1.09      -0.98     Beat    9.8
 30 2022                                                
 Jan. 31 2022  -0.90       -0.93      -0.92     Beat    0.6​
 Oct. 31 2021  -0.76       -0.79      -0.80     Missed  -1.1
 Jul. 31 2021  -0.71       -0.71      -0.66     Beat    7.4
 This summary was machine generated September 4 at 12:34 GMT. 
All figures in US dollars  unless otherwise stated